News Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
19.75 ^CAD	+0.61%		+0.41%	-6.62%

08/06	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
07/06	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top law firms in US opioid lawsuits to get hundreds of millions in fees	08/06	RE
J&J-backed Rapport Therapeutics shares debut nearly 6% higher	07/06	RE
Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	07/06	PU
J&J: FDA approves VELYS for knee arthroplasty	07/06	CF
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06	RE
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	07/06	RE
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	06/06	MT
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06	AQ
J&J: applies to FDA for expanded indication for Prezcobix	05/06	CF
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	05/06	BU
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	04/06
J&J: successful trial for Carvykti in multiple myeloma	04/06	CF
J&J: promising trial for Tecvayli in multiple myeloma	04/06	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	04/06	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	04/06	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	04/06	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	04/06	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	04/06	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	04/06	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	04/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST